New insights on SOM230, a universal somatostatin receptor ligand.
Boerlin
V
V
Novartis Pharma AG, Basel, Switzerland. viktor.boerlin@pharma.novartis.com
van der Hoek
J
J
Beglinger
Ch
Ch
Poon
K W
KW
Hartmann
S
S
Dutreix
C
C
Kovarik
J M
JM
Bruns
Ch
Ch
Weckbecker
G
G
Lewis
I
I
Schnieper
P
P
Hofland
L J
LJ
Lamberts
S W J
SW
D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004361:Drug Tolerance; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000187:drug effects* / Q000378:metabolism; D009325:Nausea / Q000209:etiology; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000145:classification / Q000187:drug effects; D012016:Reference Values; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology
D015507:Drugs, Investigational; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide